). Significant increases in heart rate (from 87 f 18 to 91 f 18 beats/min) and mean systemic arterial pressure (from 87 f 8 to 92 f 7 mm Hg) also occurred. Peak hemodynamic response occurred at various doses. Significant adverse effects associated with prenalterol consisted of increased ventricular ectopic beats in two patients and asymptomatic ventricular tachycardia in two patients. Thus, intravenous prenalterol produces hemodynamic improvement in patients with a chronic severe low output state but may be associated with increased ventricular ectopic activity.
Prenalterol
(levorotatory form of 1-isopropylamino-3-[p-hydroxyphenoxyl-Z-propanol hydrochloride) is a new catecholamine-like cardiac inotropic agent which has been shown in anima11T2 and human3-9 studies to possess relatively selective beta1 adrenergic stimulating properties, resulting in a positive inotropic response with acceptable chronotropic and vasoactive properties.
Because it is effective both orally and parenterally, it has been proposed for use in the therapy of both acute and chronic heart failure, including potential use as an adjunct or substitute for cardiac glycoside therapy in selected patients. The current study was undertaken to provide an evaluation of the hemodynamic effects of intravenously administered prenalterol in patients with severe low output heart failure.
Methods
Study patients: Nine patients (mean age 59 f 7 years) with chronic severe symptomatic heart failure (New York Heart Associationlo functional class II to IV; left ventricular filling pressure, determined from mean pulmonary arterial wedge pressure, greater than or equal to 16 mm Hg; and left ventricular ejection fraction less than or equal t.o 30 percent) were included. Seven of the nine patients were in the cardiac intensive care unit for management of heart failure at the time of investigation. Six patients had ischemic heart disease, two had idiopathic failure and one had alcoholic cardiomyopathy. The clinical diagnosis of severe left ventricular dysfunction was substantiated by cardiac catheterization with selective coronary angiography in seven patients, and in the remaining two patients it was supported by M mode echocardiography. Severe chronic impairment. of left ventricular function was present in all patients.
Eight of the nine patients had had symptoms of heart failure for at least 1 year and one patient had had such symptoms for 4 months. Six patients were in New York Heart Association functional class IV, two were in class III and one patient was in class II. Eight of the nine patients had a left ventricular third heart sound (Ss) at the t.ime of study, and seven had received venous or arterial vasodilator therapy for refractory heart failure. Because cardiac glycosides remain less than ideal agents for chronic inotropic therapy of heart failure despite 2 centuries of use, other orally effective inotropic agents are being actively investigated.
Pharmacologic features of prenalterol:
The new inotropic agent prenalterol is a derivative of phenol with a chemical structure resembling the catecholamine isoproterenol.
The presumed mechanism of action is stimulation of cardiac beta1 adrenergic receptors, which appears to be mediated directly since reserpine-treated animals maintain an inotropic response after administration of prenalterol. ' It is effective both parenterally and orally and has relatively selective inotropic effects with a smaller effect on heart rate and systemic arterial pressure.
Animal There was considerable variation in the patients' response to prenalterol (Table I) . Although increases in heart rate and systemic systolic and mean arterial pressure achieved statistical significance, it is unlikely that the modest nature of these changes would be harmful in most patients.
In individual patients, increased ischemia could result from increases in myocardial oxygen consumption (reflected by an increased pressure-rate product) greater than the increase in blood flow to ischemic tissue caused by beta1 adrenergic stimulation. 23 However, no subjective or objective evidence of aggravated ischemia was present in this study or that of Ariniego et a1.,5 who evaluated prenalterol therapy after recent myocardial infarction.
Similarly, another selective inotropic agent, 1.
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dobutamine, was not shown to exert an adverse effect on the size of myocardial infarction in experimental animals2" and in patients."5 Prenalterol and ventricular arrhythmia: The only adverse effects found in this study were cardiac arrhythmias. Although catheter-induced arrhythmias or ,arrhythmias related to the underlying disease cannot be excluded, the temporal association of the arrhythmias with drug administration suggests a causal relation. Ventricular ectopic activity has been observed with other inotropic agents including the catecholamine dobutamine26 and dopamine,27 and these agents may have been equally arrhythmogenic in the patients included in this study. Both patients with ventricular tachycardia after administration of prenalterol in this investigation received chronic oral digoxin therapy (with serum levels in the therapeutic range) for ischemic congestive cardiomyopathy after myocardial infarction, raising the possibility that the combination of prenalterol or other adrenergic inotropic agents and digoxin may induce serious ventricular arrhythmias. Increased sympathetic activity has been associated with digitalis toxicity28 and, conversely, beta adrenergic blockade has been found to be of value in the therapy of digitalisinduced cardiac arrhythmias.2g
Two of our five patients receiving long term oral digoxin therapy did not leave an increase in ventricular ectopic activity. However, the combination of severe ischemic heart failure and previous digoxin therapy appears to warrant particular caution in the administration of prenalterol.
